ORYZON Reports Financial Results and Corporate Updates for Half-Year Ending June 30, 2023
24 juil. 2023 12h47 HE
|
Oryzon Genomics, S.A.
Positive aggregate safety data from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD), consistent with safety data from seven completed clinical trials, supporting the...
Positive Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder
05 juil. 2023 08h00 HE
|
Oryzon Genomics, S.A.
Recommendation from the independent Data Monitoring Committee (DMC) to continue the PORTICO trial based on positive safety data from the initial 167 randomized patientsPORTICO plans to recruit 188...
ORYZON Announces Voting Results from its 2023 Annual General Meeting of Shareholders
27 juin 2023 08h00 HE
|
Oryzon Genomics, S.A.
All resolutions were approved.35% of the issued shares represented. MADRID, Spain and BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a...
Positive Preclinical Data of ORY-4001 for the Treatment of Charcot-Marie-Tooth (CMT) Disease Presented at the 2023 Peripheral Nerve Society (PNS) Annual Meeting
21 juin 2023 08h00 HE
|
Oryzon Genomics, S.A.
Comprehensively reversed disease progression symptoms in a CMT mice modelSelected for an oral presentationA highly selective and safe HDAC-6 inhibitorTo start IND-enabling studies soon MADRID,...
ORYZON to Present Positive Preclinical Efficacy Data of ORY-4001 in Charcot-Marie-Tooth (CMT) Disease at the 2023 Peripheral Nerve Society (PNS) Annual Meeting
30 mai 2023 08h00 HE
|
Oryzon Genomics, S.A.
Selected for Oral PresentationStudy done in the CMT1A mouse modelSupported by the CMT Research Foundation MADRID, Spain and BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN...
ORYZON to Present Trial in Progress Phase Ib FRIDA Study at the Upcoming 2023 ASCO Annual Meeting
17 mai 2023 08h00 HE
|
Oryzon Genomics, S.A.
MADRID, Spain and BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop...
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2023
10 mai 2023 09h59 HE
|
Oryzon Genomics, S.A.
Positive results from interim analysis of vafidemstat's PORTICO Phase IIb trial in Borderline Personality DisorderRecruiting patients in FRIDA trial with iadademstat in combination with gilteritinib...
ORYZON to Give Updates on Corporate Progress in May-June
09 mai 2023 08h00 HE
|
Oryzon Genomics, S.A.
BioEquity Europe 2023Foro Medcap BME 2023 VI Ibero-American Congress CEAPI 2023BIO International Conference 2023Jefferies Healthcare Conference 2023MidCap Paris 2023 MADRID and BOSTON, May 09, 2023 ...
ORYZON Announces Positive Results from Planned Interim Analysis of PORTICO, a Phase 2b Adaptive Trial in Borderline Personality Disorder
03 avr. 2023 08h00 HE
|
Oryzon Genomics, S.A.
Based on interim efficacy and safety data, Independent Data Monitoring Committee recommends continuation of the trial MADRID, Spain and BOSTON, April 03, 2023 (GLOBE NEWSWIRE) -- Oryzon...
ORYZON Announces First Patient In in FRIDA, a Phase Ib Trial With Iadademstat in Relapsed/Refractory FLT3-mutant Acute Myeloid Leukemia Patients
15 mars 2023 08h00 HE
|
Oryzon Genomics, S.A.
In combination with gilteritinibPrimary objectives: to assess safety, tolerability and RP2DSecondary objectives: to assess efficacy MADRID, Spain and BOSTON, March 15, 2023 (GLOBE NEWSWIRE) --...